4/20
12:44 pm
ktta
Pasithea Therapeutics (KTTA) had its "buy" rating reaffirmed by HC Wainwright. They now have a $3.00 price target on the stock.
Low
Report
Pasithea Therapeutics (KTTA) had its "buy" rating reaffirmed by HC Wainwright. They now have a $3.00 price target on the stock.
4/20
07:16 am
ktta
Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) [Yahoo! Finance]
High
Report
Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) [Yahoo! Finance]
4/20
07:01 am
ktta
Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1)
High
Report
Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1)
4/7
07:49 am
ktta
Pasithea Therapeutics (KTTA) was downgraded by Zacks Research from "hold" to "strong sell".
Medium
Report
Pasithea Therapeutics (KTTA) was downgraded by Zacks Research from "hold" to "strong sell".
4/1
07:16 am
ktta
Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity [TheStreet.com]
Low
Report
Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity [TheStreet.com]
4/1
07:01 am
ktta
Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity
High
Report
Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity
2/27
05:26 am
ktta
Pasithea Therapeutics Corp. (KTTA) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript [Seeking Alpha]
Medium
Report
Pasithea Therapeutics Corp. (KTTA) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript [Seeking Alpha]
2/17
07:30 am
ktta
Pasithea Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference [Yahoo! Finance]
Low
Report
Pasithea Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference [Yahoo! Finance]
2/17
07:01 am
ktta
Pasithea Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Low
Report
Pasithea Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference